Break Up Big Medicine Act
- Sponsor
- Sen. Warren, Elizabeth [D-MA]
- Committees
- Judiciary Committee (primary)
- Last action
- Feb 10, 2026
Bottom line
This bill aims to structurally separate large, vertically integrated healthcare conglomerates to eliminate conflicts of interest and restore competition, potentially reshaping the healthcare industry's corporate landscape.
What it actually does
This bill prohibits common ownership between certain healthcare entities, specifically between health insurance companies or pharmacy benefit managers (PBMs) and healthcare providers or management services organizations (MSOs), and between prescription drug or medical device wholesalers and providers or MSOs. It mandates that entities currently in violation must divest one side of their operations within one year of the Act's enactment. The bill establishes robust enforcement mechanisms for federal agencies, state attorneys general, and private citizens, including significant penalties for non-compliance and the ability to block future anti-competitive actions.
Proponents argue
Proponents argue that the bill will eliminate inherent conflicts of interest in vertically integrated healthcare platforms, fostering competition, reducing healthcare costs for patients, preventing profit-gaming, and improving care quality by removing incentives to steer patients or prescribe lucrative drugs over best treatments. They contend that current market consolidation harms patients, physicians, and taxpayers.
Opponents contend
Opponents might argue that such forced divestitures would disrupt efficient healthcare delivery, increase administrative burdens, potentially raise costs due to loss of economies of scale, and limit patient choice by breaking up integrated care models that some find convenient. They may also contend that existing antitrust laws are sufficient to address anti-competitive practices without such drastic structural intervention.
The bill is moderately complex but its core provisions are clearly stated, making it accessible for an informed reader to evaluate within a reasonable timeframe.
Section 3(a)(1)
Prohibiting Vertical Integration of Insurers/PBMs with Healthcare Providers
This provision makes it illegal for any person or entity to own, operate, or control both an insurance company or pharmacy benefit manager (PBM) AND a healthcare provider (like a physician practice, hospital, or pharmacy) or a management services organization (MSO). It mandates that entities currently in violation must divest one side of their operations within one year of the Act's enactment.
Supporters argue
Supporters argue this separation will eliminate inherent conflicts of interest where insurers or PBMs steer patients to their own providers, leading to reduced competition, higher costs, and potentially suboptimal care. It aims to restore market fairness and transparency.
Critics contend
Critics might contend that integrated systems offer efficiencies and coordinated care benefits that could be lost, potentially increasing administrative costs or disrupting patient-provider relationships. They may also argue that existing antitrust laws are sufficient to address anti-competitive practices.
Tradeoffs
Balances the potential for increased competition and reduced conflicts of interest against the disruption to existing integrated care models and potential loss of economies of scale.
Section 3(a)(2)
Prohibiting Vertical Integration of Drug/Device Wholesalers with Healthcare Providers
This provision makes it unlawful for any person or entity to own, operate, or control both a prescription drug or medical device wholesaler AND a healthcare provider or management services organization. Similar to the insurer/PBM provision, it requires divestment of one side of the operations within one year for entities currently in violation.
Section 3(b)
Enhanced Antitrust Enforcement and Divestment Penalties
This provision grants the Federal Trade Commission (FTC) and the Assistant Attorney General of the Antitrust Division joint or separate jurisdiction to enforce the common ownership prohibitions. It mandates guidance on divestment milestones within 30 days and imposes a penalty of 10% of profits transferred into escrow monthly for non-compliance. If divestment doesn't occur by the deadline, the escrowed funds are deposited into a new fund, and a divestiture trustee is appointed to oversee the sale.
Section 3(c)
Broadened Civil Action Rights and Remedies
This provision allows the Inspector General of HHS, DOJ's Antitrust Division, the FTC, and State Attorneys General to bring civil actions against violators. Crucially, it also creates a private right of action for individuals alleging damages, allowing them to seek treble damages, attorney's fees, and other relief. Courts are mandated to issue cease and desist orders, require divestment, and disgorge revenue from violations, with disgorged funds going to a new FTC-created fund for harmed communities.
Section 3(d)
Ongoing Antitrust Review of Divestitures and Future Acquisitions
This provision requires all mandated divestments to be reported to the FTC and DOJ under the Clayton Act, regardless of standard thresholds. It also tolls the divestment period during any required waiting period. Crucially, the FTC and DOJ are empowered to review the effect of both the divestiture itself and the subsequent acquisition of the divested entity on competition, financial viability, and the public interest. They can jointly or separately block any future action that would harm competition by re-creating the conflicts of interest the bill aims to eliminate.
Section 3(i)
Defining Key Terms for Scope and Application
This section provides precise definitions for critical terms such as "pharmacy benefit manager," "provider," "management services organization," and "prescription drug or medical device wholesaler." These definitions are crucial for determining which entities and activities fall under the prohibitions and enforcement actions of the Act. For example, "provider" includes a broad range of healthcare entities from physician practices to hospitals and pharmacies, identified by National Provider Institute taxonomy codes.
The definition of "provider" is very broad, including "any in-patient or outpatient pharmacy, physician practice, ambulatory surgery center, urgent care center, post-acute care facility, home-health provider, or hospital" identified by NPI taxonomy codes. The definition of "wholesale distribution" includes a detailed list of exclusions, which could be critical for some businesses.
Section 3(i) - Definitions, specifically "provider" and "wholesale distribution"
Why it matters:It is standard legislative practice to place definitions at the end, but the breadth of "provider" and the specific exclusions in "wholesale distribution" are highly consequential for the bill's practical application.
Case for: Supporters argue that broad definitions for "provider" and precise exclusions for "wholesale distribution" are necessary to ensure comprehensive coverage of the entities creating conflicts of interest while avoiding unintended regulation of legitimate, non-problematic activities.
Case against: Opponents might argue that the broad "provider" definition could sweep in entities that do not contribute to the identified conflicts, leading to unnecessary divestitures. Conversely, the detailed exclusions for "wholesale distribution" could create loopholes for some entities to maintain problematic relationships.
Estimated impact: These definitions determine the precise scope of the entire Act, affecting thousands of healthcare entities and potentially billions of dollars in assets subject to divestment.
Any revenue disgorged from civil actions will be deposited into a fund created by the Federal Trade Commission and distributed to serve the healthcare needs of the harmed community, including consumers overcharged for medical services.
Section 3(c)(7)
Why it matters:This is a detail about the disposition of funds, which is often placed in technical sections. However, it represents a significant potential benefit for consumers and a new role for the FTC in administering such a fund.
Case for: Proponents would highlight this as a direct mechanism to compensate and benefit communities and consumers who have been negatively impacted by the anti-competitive practices the bill seeks to address, ensuring that ill-gotten gains are repurposed for public good.
Case against: Critics might argue that the mechanism for distributing these funds is vague, potentially leading to bureaucratic inefficiencies or political disputes over how "healthcare needs of the harmed community" are defined and served, rather than direct restitution to individuals.
Estimated impact: Could involve millions or billions of dollars in disgorged profits, potentially creating a substantial new funding stream for community health initiatives.